Global Switch Expands Its European Footprint as Construction Begins at its Amsterdam Data Centre Campus
Global Switch, a leading owner, operator and developer of large scale network dense, carrier and cloud neutral multi-tenanted data centres in Europe and Asia-Pacific has announced that in response to growing demand construction has started on the first stage of a new data centre in Amsterdam.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200624005069/en/
Global Switch Amsterdam East (Photo: Business Wire)
The 32,000 sq m data centre, Global Switch Amsterdam East, will be built immediately adjacent to the existing Amsterdam West facility located in the Slotervaart/Overtoomseveld district, close to the main Dutch cable infrastructure, the financial district and city centre. Global Switch Amsterdam is the only multi-tenant provider in the city with a dedicated mains supply, and once all stages of the new data centre are complete, the utility power supply capacity will increase by 40MVA, bringing the campus total to 72MVA supplied at 50kV.
In contrast to the recent moratorium on granting new data centre planning consents, importantly Global Switch Amsterdam East is a known project with Gemeente Amsterdam (City of Amsterdam) and is not impacted either by the widely announced ‘building stop’ or affected by power availability across the Metropolitan Region of Amsterdam.
Similar to other Global Switch developments, energy efficiency is at the core of the design. Amsterdam East will incorporate the latest technologies such a flooded room cooling design with hot aisle containment allowing flexible IT rack load deployment. The cooling will be generated using a free-cooling water-based cooling system and will allow the heat to be exported to the local community. The data centre will be targeting an annualised design Power Usage Effectiveness (PUE) of less than 1.2 and a BREEAM "Very Good" certification. In addition, as part of Global Switch’s comprehensive Energy Management Programme, customers will be offered 100% green energy.
John Corcoran, CEO Global Switch,said, “We are continuing to see demand for high quality, resilient and energy efficient data centres providing multiple connectivity options particularly from global hyperscale cloud providers looking for highly experienced data centre operators, such as Global Switch, as well as demand from European, US and Asian customers. We are therefore delighted to have now started construction of Global Switch Amsterdam East which will be our fourteenth data centre.”
Jasper Lankhorst, Managing Director Global Switch Amsterdam,said, “It is very exciting to be announcing this substantial addition of world class technical data centre capacity to our Amsterdam campus, particularly at a time when there is a permit stop for new data centre developments in the city and a shortage in power availability in some places of the Amsterdam Metro Area. With the acceleration of the digital economy, Global Switch Amsterdam East will provide an Open Compute Platform ready environment enabling customers to deploy at scale both with speed and cost effectively. As with all our data centres, customers will also benefit from bespoke data centre solutions, as well as a highly resilient and secure space for housing mission critical IT equipment.”
Global Switch Amsterdam West is a core node not just for the Netherlands, but also for Europe and beyond. It is one of the most connected hubs in the country and currently hosts a multitude of global and national telecommunications and cloud providers, AMS-IX and NL-IX as well as a wide range of internet services providers. With direct fibre connections between the two data centres, customers of Amsterdam East will be able to access this connectivity rich environment and will benefit from a wide choice of cloud and network providers as well as direct access to the global IP backbone. The two data centres will provide a total of four diverse entry points and four interconnected Meet Me Rooms ensuring highly resilient connections.
Peter van Burgel, CEO, AMS-IX, said, “We welcome this news by our long-term partner Global Switch. This announcement underlines the importance of the Amsterdam region as one of the largest connectivity hubs in the world and as a desirable climate for digital businesses. It also shows that the digitalisation continues to be a strong, sustainable driver for growth, even in a time when building options are challenging and the economic outlook is uncertain.”
Stijn Grove, Managing Director Dutch Data Center Association (DDA),said, “The impact of digitalisation on our economy and society is immense. The recent events have only made people more aware that digitalisation is the sustainable way forward to grow our economy. A sound digital foundation is of crucial importance to achieve this. The Metro Region Amsterdam (MRA) is one of the key data hubs in the world and known as the Digital Gateway to Europe. Global Switch’ expansion in the MRA region will strengthen this international position as key data hub even further, and the Dutch and international economy as a whole. We are proud to have Global Switch as a member of the association and congratulate them with their expansion.”
- Full access to the existing network-dense, low-latency environment with a multitude of carriers and network service providers.
- Access to peering platforms AMS-IX, NL-IX and all major cloud platforms.
- Hyperconnected and ideally located adjacent to the main regional and international fibre routes.
- Built in accordance to the highest operational standards with matching SLA’s.
- Bespoke solutions with scalable space and power.
- Open Compute Platform (OCP) facility compliance.
- Environmentally sustainable targeting a PUE of less than 1.2.
- Certified ISO9001, 14001, 27001, 50001, OHSAS 18001, AMS-IX, PCI-DSS, ISAE 3402 compliant.
About Global Switch
Global Switch is a leading owner, operator and developer of large-scale, carrier and cloud neutral, multi-customer data centres in Europe and Asia-Pacific. Founded in 1998, Global Switch has a proven business model, demonstrable track record and is the highest credit rated data centre company in the world with investment grade credit ratings from Fitch, Moody’s and Standard & Poor’s.
Global Switch is a vital and strategic partner for customers that require secure and resilient data centre services with scalable capacity and a high-level customer service. The Company's focus is on highly resilient, central, low latency, network dense locations in prime city centre locations and internet hubs close to its customers on the edge of financial and business districts. Global Switch’s data centres operate exclusively in the Tier I markets of Europe and Asia-Pacific to Tier III or higher and currently total around 390,000 sq m (4,200,000 sq ft) of floor space and are occupied by a broad range of customers, global and national, large and small including government organisations, financial institutions, enterprises, global systems integrators, telecommunication carriers, cloud and managed service providers and other hosting businesses.
For more information visit: www.globalswitch.com
FOR MEDIA ENQUIRIES OR FURTHER INFORMATION PLEASE CONTACT:
Group Director, Marketing & Communications
+44 20 8054 9053
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Presents New Data Highlighting Scientific Advancements in Lung Cancer at ESMO Virtual Congress18.9.2020 12:55:00 CEST | Press release
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the company is presenting data from its lung cancer portfolio at the virtual European Society for Medical Oncology (ESMO) conference. Notably, insights from sub-analyses of the Phase 3 ALTA 1L study reinforce both the compelling evidence of intracranial efficacy with ALUNBRIG® (brigatinib) as a first-line treatment for patients with anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) as well as associated quality of life (QoL) data. Takeda is also featuring updated 10-month follow-up results from the Phase 1/2 trial of mobocertinib (TAK-788), demonstrating mobocertinib achieved a duration of response (DoR) of more than one year in the trial’s study population of patients with epidermal growth factor receptor (EGFR) Exon20 insertion+ metastatic NSCLC (mNSCLC). “We’re pleased to present our ongoing research in lung cancer at this year’s virtual ESMO congress, including new
Incyte Announces Encouraging Results From Phase 2 Trial of Retifanlimab (INCMGA0012) in Patients With Previously Treated, Advanced Squamous Cell Carcinoma of the Anal Canal18.9.2020 12:00:00 CEST | Press release
Incyte (Nasdaq:INCY) today announced results from its Phase 2 POD1UM-202 trial evaluating retifanlimab, a PD-1 inhibitor, in previously treated patients with advanced squamous cell carcinoma of the anal canal (SCAC) who have progressed following standard platinum-based chemotherapy. The trial enrolled 94 patients, including those with well-controlled human immunodeficiency virus (HIV) infection (10%). Retifanlimab monotherapy resulted in a confirmed objective response rate (ORR) of 14% as determined by independent central review (ICR) using RECIST v1.1. Responses were observed regardless of PD-L1 status, presence of liver metastases, age or HIV+ status. Retifanlimab was generally well-tolerated with a safety profile as expected of a PD-1 inhibitor and no loss of HIV infection control. Key findings from POD1UM-202: N=94 ORR* (95% CI) 13.8% (7.6-22.5) Best OR*, n 1 CR 12 PR 33 SD DCR 48.9% DOR, median (95% CI), months 9.5 (5.6-NE) PFS, median (95% CI), months 2.3 (1.9-3.6) OS, median (95
Sigfox and Cube Infrastructure Managers Announce Major Partnership in IoT Infrastructure18.9.2020 09:30:00 CEST | Press release
Sigfox, the global 0G network1 and cloud provider for industrial data, is proud to announce a new strategic alliance with Cube Infrastructure Managers (Cube), through the sale of its German 0G network to Cube. Sigfox has grown its 0G IoT services by rolling out 0G networks across 72 countries and regions, which was largely achieved with partners called Sigfox Operators. These operators are the owners of the 0G networks, which they operate as exclusive connectivity providers of Sigfox IoT services, offering worldwide connectivity to customers. The sale of the German network to Cube will allow Sigfox to finance its continued innovation efforts in data value extraction and improvements in cloud algorithms to reduce energy consumption and allow the implementation of even more cost-effective devices and sensors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200918005116/en/ Cube Infrastructure Managers, the European infrastructu
Sensorion successfully raises approximately €31 (US$ 36.5) million in an oversubscribed private placement to US and European investors18.9.2020 08:00:00 CEST | Press release
Regulatory News: Not for release, publication or distribution, directly or indirectly, in or into the United States, Canada, Australia or Japan. This press release is not intended as an offer and is for informational purpose only Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN – the “Company”) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders announces today the success of its previously announced capital increase. The Company has placed 18,236,000 new ordinary shares with a nominal value of €0.10 each (the “New Shares”), for total gross proceeds of approximately € 31 million by means of an accelerated bookbuild offering to the benefit of categories of persons (the “Reserved Offering”). The issue price of the New Shares is €1.70 per share, representing a 3.5% discount to the weighted average share price on the day preceding the date on which the issuance price
Vifor Pharma Group Announces Successful Sale of OM Pharma18.9.2020 07:00:00 CEST | Press release
Regulatory News: Vifor Pharma has today announced the successful sale of 100% of the share capital of OM Pharma, a Vifor Pharma Group company to Optimus Holding Ltd. The terms of the deal include: A purchase consideration of MCHF 435 for 100% of the share capital An earn out related to potential future value gains on 20% of Optimus Holding Ltd. equity to be determined before the end of 2027 upon a trade sale, IPO or EBITDA multiple This earn out together with the purchase consideration could result in a total transaction value exceeding MCHF 500. The deal is expected to close within 30 days. OM Pharma is a Geneva-based company mainly active in the field of microbial derived immunotherapeutics and has developed strongly outside the core strategy of Vifor Pharma over the past few years. Optimus Holding Ltd. is a Swiss Group, founded by Etienne Jornod together with long-standing Swiss entrepreneurs and Abdi Ibrahim (28.5%), a Turkey-based pharmaceutical company operating in 12 countries a
ESMO 2020: Phase II CLARINET FORTE Results Show Increasing Dose Frequencies of Somatuline ® Autogel ® (lanreotide) Allows Patients with NETs to Delay Treatment Escalation by up to 8.3 Months18.9.2020 07:00:00 CEST | Press release
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the release of first efficacy and safety data from the CLARINET FORTE study, with the abstract to be presented as a mini-oral presentation at the 2020 European Society for Medical Oncology (ESMO) Congress, taking place virtually from 19-21 September 2020. The prospective single-arm, open-label, exploratory, international Phase II study investigated the efficacy and safety of increasing the dose frequency of Somatuline® Autogel®(lanreotide) in patients with pancreatic or midgut NETs with centrally-assessed progression within the last two years while on a standard lanreotide regimen for ≥24 weeks. An extension of progression-free survival (PFS) rates and encouraging disease-control rates (DCR) were recorded in both tumor types, with no new safety signals. “These results support a clinically meaningful benefit to a population of patients with high unmet medical need by potentially delaying escalation to more toxic treatmen